Top Industry Leaders in the Oral Thrush Market
GlaxoSmithKline (GSK) acquires Paratek Pharmaceuticals: December 2023 deal bolsters GSK's antifungal portfolio, giving them access to Paratek's leading oral thrush medication, Noxafil (posaconazole).
Theravance Biopharma Collaborates with Almirall Laboratories: September 2023 partnership focuses on developing new antifungal therapies for oral thrush and other fungal infections, potentially leading to more effective and targeted treatment options.
Mylan Laboratories launches generic miconazole for oral thrush: October 2023 approval broadens access to a cost-effective treatment option for patients in the US.
Bayer receives EU approval for Canesten® (clotrimazole) 10mg lozenges: November 2023 approval offers a new formulation for treating oral thrush in adults, providing an alternative to traditional oral gels or suspensions.
List of Oral Thrush Key Companies in the Market
- Bayer AG
- Teva Pharmaceuticals
- Stellar Pharma
- Pfizer Inc.
- Wockhardt Ltd.
- Ranbaxy Laboratories Limited
- Bristol Laboratories
- Glenmark Pharmaceuticals
- GlaxoSmithKline Plc